Exact Sciences delivered robust Q3 2024 results, with total revenue increasing 13% year-over-year to $708.7 million. The company achieved record test volumes for Cologuard and Oncotype DX, serving 1.2 million patients. Screening revenue grew 15% to $544.9 million, while Precision Oncology revenue rose 5% to $163.8 million.The FDA approved Cologuard Plus, Exact Sciences' next-generation colorectal cancer screening test, setting a new performance standard with 95% cancer sensitivity and 43% advanced precancerous lesion sensitivity at 94% specificity. The company expects to launch Cologuard Plus with Medicare coverage and guideline inclusion in 2025, potentially expanding its addressable market of 60 million Americans not up-to-date with colon cancer screenings.Exact Sciences continues to advance its product pipeline, including the development of a blood-based colorectal cancer screening test and a multi-cancer screening test. The company presented promising data for these tests at major scientific conferences and initiated real-world evidence studies. Despite ongoing investments in research and development, Exact Sciences improved its cash position, generating $138.7 million in cash from operations in Q3, a significant improvement from the previous year.

Exact Sciences delivered robust Q3 2024 results, with total revenue increasing 13% year-over-year to $708.7 million. The company achieved record test volumes for Cologuard and Oncotype DX, serving 1.2 million patients. Screening revenue grew 15% to $544.9 million, while Precision Oncology revenue rose 5% to $163.8 million.The FDA approved Cologuard Plus, Exact Sciences' next-generation colorectal cancer screening test, setting a new performance standard with 95% cancer sensitivity and 43% advanced precancerous lesion sensitivity at 94% specificity. The company expects to launch Cologuard Plus with Medicare coverage and guideline inclusion in 2025, potentially expanding its addressable market of 60 million Americans not up-to-date with colon cancer screenings.Exact Sciences continues to advance its product pipeline, including the development of a blood-based colorectal cancer screening test and a multi-cancer screening test. The company presented promising data for these tests at major scientific conferences and initiated real-world evidence studies. Despite ongoing investments in research and development, Exact Sciences improved its cash position, generating $138.7 million in cash from operations in Q3, a significant improvement from the previous year.